NIH Reporter #3R01CA263806-05S1

NCI Solicitation for Research on Cisplatin-Induced Neurotoxicity in Ovarian Cancer

This opportunity is issued by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for research on cisplatin-induced neurotoxicity in ovarian cancer. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Research Focus: - Investigate neurotoxicity caused by cisplatin chemotherapy in ovarian cancer - Emphasis on the p38 MAPK and JNK molecular pathways - Goal to develop therapeutics that reduce neuropathy and cognitive decline in women - Research Organization: - University of California-Irvine is mentioned as a participant - Products/Services Requested: - Research services (no specific products, part numbers, or quantities listed) - Unique Requirements: - Expertise in neurotoxicity, ovarian cancer, and molecular pathway analysis (p38 MAPK, JNK) - Focus on translational research to develop new therapeutics - No OEMs or commercial vendors are specified in the solicitation - No product procurement is involved; this is a research grant opportunity

Description

This NIH grant opportunity supports research focused on neurotoxicity related to cisplatin in ovarian cancer. The project aims to investigate the p38 MAPK and JNK pathways to develop therapeutics that reduce side effects such as neuropathy and cognitive decline in women undergoing chemotherapy. The research is conducted by the University of California-Irvine under the National Cancer Institute (NCI), part of the NIH.

View original listing